# Embecta Corp. (EMBC)

> Source: Nexqual · https://nexqual.com/EMBC · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Embecta Corp. (EMBC), nexqual.com/EMBC" · informational, not investment advice.

**Price:** USD 6.45 (+4.37% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 6.18 · day 6.19–6.58 · 52w 2.77–14.91 · market cap $365M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.02B, net income $87.5M (8.6% margin), free cash flow $165M (SEC filings).
- Valuation: P/E 4.2x (avg 10.5x at the last 3 fiscal year-ends), EV/EBITDA 6.0x, net debt $1.24B.
- 1 of 80 tracked superinvestors hold EMBC (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Sell (mean 3.50 on a 1–5 scale) (4 analysts), mean target USD 4 (range 3–5).
- Total return with dividends: 1Y -51.3% vs S&P 500 +18.1%; 5Y -82.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-25, EPS estimate USD 0.29, revenue estimate $270M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.17B | $1.13B | $1.12B | $1.12B | $1.08B | $1.02B |
| Gross profit | $800M | $775M | $750M | $735M | $677M | — |
| Operating income | $492M | $310M | $222M | $167M | $242M | $224M |
| Net income | $415M | $224M | $70.4M | $78.3M | $95.4M | $87.5M |
| EPS (diluted) | $7.28 | $3.89 | $1.22 | $1.34 | $1.62 | — |
| Free cash flow | $420M | $389M | $41.2M | $19.9M | $182M | $165M |
| Gross margin | 68.7% | 68.6% | 66.9% | 65.5% | 62.6% | — |
| Operating margin | 42.2% | 27.4% | 19.8% | 14.9% | 22.4% | 21.9% |
| Net margin | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% | 8.6% |
| Revenue growth | +7.4% | -3.1% | -0.8% | +0.2% | -3.8% | — |
| Cash + short-term investments | $0K | $331M | $326M | $268M | $226M | — |
| Total debt | $0K | $1.61B | $1.60B | $1.57B | $1.40B | — |
Fiscal years end Sep. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 4.2x · P/S 0.4x · EV/EBITDA 6.0x · EV/Sales 1.6x · P/FCF 2.2x · FCF yield 45.04% · Earnings yield 23.94% · Dividend yield (paid, TTM) 7.44% · Net debt $1.24B · EV $1.61B
P/E at fiscal year-ends: Sep 2025 8.7x, Sep 2024 10.5x, Sep 2023 12.3x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold EMBC. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Yacktman Asset Management |  | 0.17% | $14.1M | Added +17.5% |

## Analysts
Consensus Sell (mean 3.50 on a 1–5 scale), 4 analysts; mean target USD 4 (low 3, high 5).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2022-03-21) |
|---|---|---|
| Total return | -51.3% | -82.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -51.5% | -31.8% |
| Volatility (annualized) | 103.1% | 72.5% |
| Max drawdown | -79.6% (Nov 2025→May 2026) | -91.7% (Mar 2022→Jun 2026) |

## Peers (Medical Instruments & Supplies)
XRAY (DENTSPLY SIRONA Inc.) USD 8.83 +3.76% · LMAT (LeMaitre Vascular, Inc.) USD 83.16 +1.97% · ATRC (AtriCure, Inc.) USD 57.78 +1.60% · WRBY (Warby Parker Inc.) USD 24.59 -7.28% · PLSE (Pulse Biosciences, Inc) USD 45.59 -6.08% · NVST (Envista Holdings Corporation) USD 23.5 +3.75%

## More
Full page: https://nexqual.com/EMBC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt